1. Home
  2. RWAY vs IPHA Comparison

RWAY vs IPHA Comparison

Compare RWAY & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Runway Growth Finance Corp.

RWAY

Runway Growth Finance Corp.

HOLD

Current Price

$5.45

Market Cap

226.3M

Sector

N/A

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.76

Market Cap

189.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RWAY
IPHA
Founded
2015
1999
Country
United States
France
Employees
N/A
163
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
226.3M
189.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RWAY
IPHA
Price
$5.45
$1.76
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$9.50
$5.75
AVG Volume (30 Days)
646.1K
6.3K
Earning Date
05-07-2026
03-26-2026
Dividend Yield
21.54%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.26
$180.36
Revenue Next Year
$1.25
N/A
P/E Ratio
$5.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.19
$1.18
52 Week High
$11.20
$2.63

Technical Indicators

Market Signals
Indicator
RWAY
IPHA
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
RWAY
IPHA

About RWAY Runway Growth Finance Corp.

Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States. The company's investment objective is to maximize its total return to its stockholders through current income on its loan portfolio, and secondarily through capital gain on its warrants and other equity positions.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: